Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Yifei III
- Development stage
- Preclinical
- Lead developer
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Jianpi Yifei III is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine for the treatment of stable chronic obstructive pulmonary disease (COPD). Administered as oral granules, the drug is designed to address the TCM syndrome of lung-spleen qi deficiency. It is part of a series of 'Jianpi Yifei' formulations (including Jianpi Yifei II) used to manage respiratory and neuromuscular conditions. Clinical evaluation of Jianpi Yifei III focuses on its ability to reduce the frequency of acute exacerbations and improve the quality of life in COPD patients.
- Other names
- Jianpi Yifei III granulesJianPi YiFei III
02
Targets
IL-6 (Interleukin 6)IL8 (C-X-C Motif Chemokine Ligand 8)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Jianpi Yifei III.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jianpi Yifei III.